Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Gemcitabine is an antimetabolite ranking among the most prescribed anticancer drugs worldwide. This nucleoside analog exerts its antiproliferative action after tumoral conversion into active triphosphorylated nucleotides interfering with DNA synthesis and targeting ribonucleotide reductase. Gemcitabine is a mainstay for treating pancreatic and lung cancers, alone or in combination with several cytotoxic drugs (nab-paclitaxel, cisplatin and oxaliplatin), and is an option in a variety of other solid or hematological cancers. Several determinants of response have been identified with gemcitabine, i.e., membrane transporters, activating and inactivating enzymes at the tumor level, or Hedgehog signaling pathway. More recent studies have investigated how germinal genetic polymorphisms affecting cytidine deaminase, the enzyme responsible for the liver disposition of gemcitabine, could act as well as a marker for clinical outcome (i.e., toxicity, efficacy) at the bedside. Besides, constant efforts have been made to develop alternative chemical derivatives or encapsulated forms of gemcitabine, as an attempt to improve its metabolism and pharmacokinetics profile. Overall, gemcitabine is a drug paradigmatic for constant searches of the scientific community to improve its administration through the development of personalized medicine in oncology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805 · cited 1×
“This rising concern in both experimental and clinical oncology about the role Hedgehog protein plays, highlights the fact that beyond pharmacological molecular determinants, the issue of drug delivery becomes more and more critical [96, 97].”
BackgroundDrug Resistance and the Solid Tumor Microenvironment
Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116 · cited 1×
“This rising concern in both experimental and clinical oncology about the role Hedgehog protein plays, highlights the fact that beyond pharmacological molecular determinants, the issue of drug delivery becomes more and more critical [96, 97].”
BackgroundCellular pharmacology of gemcitabine
Mini, E., Nobili, S., Caciagli, B., Landini, I., & Mazzei, T. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj941 · Cited by 842
Basis for effective combination cancer chemotherapy with antimetabolites
Peters, G. J., van der Wilt, C. L., van Moorsel, C. J. A., Kroep, J. R., Bergman, A. M., & Ackland, S. P. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(00)00086-3 · Cited by 301
Self-citation
Cited by
Deoxycytidine release from pancreatic stellate cells promotes gemcitabine resistance
Dalin, S., Sullivan, M. R., Lau, A. N., Grauman-Boss, B., Mueller, H. S., Kreidl, E., Fenoglio, S., Luengo, A., Lees, J. A., Vander Heiden, M. G., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0960 · Cited by 156
Gemcitabine nanoparticles promote antitumor immunity against melanoma
Zhang, Y., Bush, X., Yan, B., & Chen, J. A. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2018.10.022 · Cited by 117
McNamara, M. G., Bridgewater, J., Palmer, D. H., Faluyi, O., Wasan, H., Patel, A., Ryder, W. D., Barber, S., Gnanaranjan, C., Ghazaly, E., et al. (2021) · The Oncologist · doi:10.1002/onco.13598 · Cited by 25
Liu, X., Gündel, B., Li, X., Liu, J., Wright, A., Löhr, M., Arvidsson, G., & Heuchel, R. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101107 · Cited by 24
Metadata
- Authors
- Ciccolini, J., Serdjebi, C., Peters, G. J., & Giovannetti, E.
- Venue
- Cancer Chemotherapy and Pharmacology
- Published
- 2016-03-23
- Volume
- 78
- Issue
- 1
- Pages
- 1-12
- ISSN
- 0344-5704 (ISSN-L)
- 1432-0843
- OpenAlex
- W2312132282
- Cited by
- 241
- References
- 4
- FWCI
- 19.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.